South & Central America Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis

Description

List of Tables

The South & Central America overactive bladder treatment market is expected to grow from US$ 472.49 million in 2022 to US$ 543.53 million by 2028; it is estimated to grow at a CAGR of 2.4% from 2022 to 2028.

Increasing Number of Mergers and Acquisitions is Propelling South & Central America Overactive Bladder Treatment Market Growth

Through mergers and acquisitions (M&A), companies can gain a competitive edge by entering new markets and acquiring new technologies. The ongoing mergers and acquisitions in the overactive bladder treatment market are creating growth opportunities for various companies. In July 2021, Uro Medical strengthened its urology portfolio with the acquisition of Micron Medical, which offers wirelessly powered, injectable, microtechnology neurostimulators focused on treating overactive bladder. These neurostimulators, which can be easily incorporated into patients' daily lives, offer a convenient, safe, minimally invasive, and cost-effective urological treatment option. In February 2021, Axonics Modulation Technologies, Inc.-a medical technology company-acquired Contura Ltd. and its proprietary product, Bulkamid, which is a urethral bulking agent for women with stress urinary incontinence (SUI). Axonics produces and markets novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction. The acquisition of Contura Ltd. provides an opportunity to expand its SNM business across the world and serve the large, highly underpenetrated SUI market. The company plans to offer urogynecologists and urologists a complete suite of clinically differentiated incontinence solutions to treat their patients. Thus, increasing number of mergers and acquisitions is propelling South & Central America overactive bladder treatment market growth

South & Central America Overactive Bladder Treatment Market Overview

The South & Central America overactive bladder treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil is expected to account for the largest share of the market in the region, and it is projected to register the highest CAGR during the forecast period. The market growth is attributed to the growing geriatric population and rising prevalence of chronic disorders. The region is witnessing the high prevalence of obesity, unhealthy lifestyle patterns, and other risks, which are contributing to overactive bladder syndrome. As a result, the awareness of overactive bladder treatment has increased across the region, which is influencing the market growth in the region.

South & Central America Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)

South & Central America Overactive Bladder Treatment Market Segmentation

The South & Central America overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.

Based on pharmacotherapy, the South & Central America overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022.

Based on disease type, the South & Central America overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.

Based on country, the South & Central America overactive bladder treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the market in 2022.

AbbVie Inc; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the South & Central America overactive bladder treatment market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South & Central America overactive bladder treatment market
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the South & Central America overactive bladder treatment market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the overactive bladder treatment market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

Product Code: BMIRE00027968

1. Introduction

1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 SAM Overactive Bladder Treatment Market- By Pharmacotherapy
- 1.3.2 SAM Overactive Bladder Treatment Market- By Disease Type
- 1.3.3 SAM Overactive Bladder Treatment Market - By Country

2. SAM Overactive Bladder Treatment Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. SAM Overactive Bladder Treatment Market - Market Landscape

4.1 Overview
4.2 SAM PEST Analysis
4.3 Expert Opinion

5. SAM Overactive Bladder Treatment Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increase in Prevalence of Urinary Incontinence
- 5.1.2 Growing Incidence of Urinary Tract Infections
5.2 Key Market Restraints
- 5.2.1 Recalls of Therapeutic Drugs
5.3 Key Market Opportunities
- 5.3.1 Increasing Number of Mergers and Acquisitions
5.4 Future Trends
- 5.4.1 Robust Pipeline of Drugs and Successive Launch of Novel Therapies
5.5 Impact analysis

6. SAM Overactive Bladder Treatment Market - SAM Analysis

6.1 SAM Overactive Bladder Treatment Market Revenue Forecast and Analysis

7. SAM Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy

7.1 Overview
7.2 SAM Overactive Bladder Treatment Market, By Pharmacotherapy 2021 & 2028 (%)
7.3 Mirabegron
- 7.3.1 Overview
- 7.3.2 Mirabegron: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.4 Botox
- 7.4.1 Overview
- 7.4.2 Botox: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.5 Neurostimulation
- 7.5.1 Overview
- 7.5.2 Neurostimulation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.3 Transcutaneous Sacral Nerve Stimulation
  - 7.5.3.1 Overview
  - 7.5.3.2 Transcutaneous Sacral Nerve Stimulation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.4 Transcutaneous Tibial Nerve Stimulation
  - 7.5.4.1 Overview
  - 7.5.4.2 Transcutaneous Tibial Nerve Stimulation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.5 Percutaneous Posterior Tibial Nerve Stimulation
  - 7.5.5.1 Overview
  - 7.5.5.2 Percutaneous Posterior Tibial Nerve Stimulation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.6 Others
  - 7.5.6.1 Overview
  - 7.5.6.2 Others: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Anticholinergics
- 7.6.1 Overview
- 7.6.2 Anticholinergics: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.3 Solifenacin
  - 7.6.3.1 Overview
  - 7.6.3.2 Solifenacin: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.4 Oxybutynin
  - 7.6.4.1 Overview
  - 7.6.4.2 Oxybutynin: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.5 Fesoterodine
  - 7.6.5.1 Overview
  - 7.6.5.2 Fesoterodine: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.6 Darifenacin
  - 7.6.6.1 Overview
  - 7.6.6.2 Darifenacin: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.7 Tolterodine
  - 7.6.7.1 Overview
  - 7.6.7.2 Tolterodine: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.8 Trospium
  - 7.6.8.1 Overview
  - 7.6.8.2 Trospium: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.9 Other Anticholinergics
  - 7.6.9.1 Overview
  - 7.6.9.2 Other Anticholinergics: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.7 Intravesical Instillation
- 7.7.1 Overview
- 7.7.2 Intravesical Instillation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)

8. SAM Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type

8.1 Overview
8.2 SAM Overactive Bladder Treatment Market, By Disease Type 2021 & 2028 (%)
8.3 Idiopathic Overactive Bladder
- 8.3.1 Overview
- 8.3.2 Idiopathic: Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Neurogenic Overactive Bladder
- 8.4.1 Overview
- 8.4.2 Neurogenic: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)

9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis

Overview

9.1.2 SAM: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
- 9.1.2.1 Brazil: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
- 9.1.2.2 Brazil: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
- 9.1.2.3 Brazil: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (USD Million)
  - 9.1.2.3.1.1 Brazil: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
  - 9.1.2.3.1.2 Brazil Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
- 9.1.2.4 Brazil: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (USD Million)
9.1.3 Argentina: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
- 9.1.3.1 Argentina: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
  - 9.1.3.1.1 Argentina: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (USD Million)
  - 9.1.3.1.1.1 Argentina: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
  - 9.1.3.1.1.2 Argentina Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
  - 9.1.3.1.2 Argentina: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (USD Million)
- 9.1.3.2 Rest of SAM: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
  - 9.1.3.2.1 Rest of SAM: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
  - 9.1.3.2.2 Rest of SAM: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (USD Million)
  - 9.1.3.2.2.1 Rest of SAM: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
  - 9.1.3.2.2.2 Rest of South & Central America Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
  - 9.1.3.2.3 Rest of SAM: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (USD Million)

10. Overactive Bladder Treatment Market- Industry Landscape

10.1 Overview
10.2 Organic Developments
- 10.2.1 Overview

11. Company Profiles

11.1 Astellas Pharma Inc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 AbbVie Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Teva Pharmaceutical Industries Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Endo Pharmaceuticals Inc.
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Hisamitsu Pharmaceutical Co., Inc.
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Medtronic Plc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Pfizer Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms